论文部分内容阅读
钙磷代谢紊乱是慢性肾脏病(CKD)患者常见且严重的并发症,有效控制血钙、血磷水平是降低该类患者各类临床并发症和改善预后的关键,与CKD患者尤其是维持性血液透析患者的预后密切相关。目前纠正钙磷代谢紊乱的主要治疗措施包括饮食限磷,使用磷结合剂、活性维生素D及其衍生物制剂,以及甲状旁腺切除术。非铝、非钙新型磷结合剂为钙磷代谢紊乱的治疗提供了新方向。本文简要综述CKD继发钙磷代谢紊乱的治疗研究进展。
The disorder of calcium and phosphorus metabolism is a common and serious complication in patients with chronic kidney disease (CKD). Effective control of serum calcium and phosphorus levels is the key to reduce various clinical complications and improve prognosis of patients with CKD. In particular, The prognosis of hemodialysis patients is closely related. At present, the main therapeutic measures to correct the disorder of calcium and phosphorus metabolism include dietary phosphorus limitation, the use of phosphate binders, active vitamin D and its derivatives preparations, and parathyroidectomy. Non-aluminum, non-calcium new phosphate binding agent for the treatment of disorders of calcium and phosphorus provides a new direction. This article briefly reviewed CKD secondary calcium and phosphorus metabolism disorders treatment progress.